Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 109Endometrial Neoplasms 16Neoplasm Metastasis 10Polycystic Ovary Syndrome 9Ovarian Neoplasms 7Neoplasms 7Advanced Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Recurrence 3Infertility 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Squamous Cell Carcinoma of Head and Neck 2Progesterone Resistance 2Neoplasms by Site 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Endometrial Hyperplasia 2Cystadenocarcinoma, Serous 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Breast Cancer Metastatic 2Breast Cancer Female 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Estrogen Receptor-positive Breast Cancer × Letrozole × 1 year × Clear all
NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Completed
31 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡